What is the exact date of apotex's ruxolitinib andas submission in the us?

Apotex's ruxolitinib ANDA submission date

Apotex filed its Abbreviated New Drug Application for ruxolitinib in the United States on 28 March 2023. The submission followed the FDA's acceptance of the application for review in October 2023.

When does the patent for Jakafi expire?

The primary U.S. patent covering ruxolitinib (U.S. Patent 7,598,257) is scheduled to expire on 3 December 2026. Additional patents listed in the Orange Book extend exclusivity into 2027 for certain formulations.

Why are companies challenging the Jakafi patents?

Multiple generic firms, including Apotex, have filed Paragraph IV certifications asserting that the patents are invalid or not infringed. These challenges typically aim to clear the path for earlier generic entry before the listed expiration dates.

How does Apotex's filing compare with other ruxolitinib ANDAs?

At least four other companies (Teva, Hetero, MSN, and Zydus) have also submitted ANDAs for ruxolitinib. Apotex's March 2023 filing places it among the earlier challengers, though the exact order of filings remains confidential until patent litigation details surface.

Can biosimilars or generics launch before patent expiry?

A successful Paragraph IV challenge or settlement could allow Apotex or other filers to launch before December 2026. No settlement has been publicly announced, and litigation remains ongoing.

What side effects are patients asking about with ruxolitinib generics?

Patients frequently inquire about differences in adverse events between brand Jakafi and potential generics, particularly regarding anemia, thrombocytopenia, and infection risk. Regulatory reviews will compare these profiles using the same reference data.

Source: DrugPatentWatch.com